Get the Stockscreener App
15.50
0.26%
-0.04
Tourmaline Bio Inc stock is traded at $15.50, with a volume of 170.22K.
It is down -0.26% in the last 24 hours and up +10.01% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$15.54
Open:
$15.46
24h Volume:
170.22K
Relative Volume:
0.52
Market Cap:
$395.35M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
26.79
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+0.71%
1M Performance:
+10.01%
6M Performance:
-42.34%
1Y Performance:
+7.49%
1-Day Range:
$14.68
$15.63
1-Week Range:
$14.68
$16.32
52-Week Range:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
15.50 | 395.35M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks
Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World
Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World
Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World
FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World
Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World
FY2025 EPS Estimates for Tourmaline Bio Raised by Analyst - Defense World
Tourmaline Bio Q2 EPS Estimate Decreased by HC Wainwright - Defense World
Analysts Set Expectations for Tourmaline Bio Q2 Earnings - Defense World
HC Wainwright Predicts Tourmaline Bio Q2 Earnings - Defense World
Wells Fargo & Company MN Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Reports Q1 2025 Financial Results - TipRanks
Tourmaline Bio’s (TRML) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Tourmaline Bio (NASDAQ:TRML) Receives “Buy” Rating from HC Wainwright - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Invesco Ltd. Purchases 1,181 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
CVS Health (NYSE:CVS) Price Target Raised to $71.00 - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. SEC 10-Q Report - TradingView
Tourmaline (TRML) Projects Financial Stability into Late 2027 | TRML Stock News - GuruFocus
Tourmaline (TRML) Anticipates Key Data from Phase 2 Trial of Pacibekitug | TRML Stock News - GuruFocus
Tourmaline Bio, Inc. Confirms Progress in Phase 2 TRANQUILITY Trial and Financial Position Ahead of Key Data Readout - Nasdaq
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio Advances Key Cardiovascular Trial With $275M War Chest: Q2 Results Coming - Stock Titan
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Legal & General Group Plc - Defense World
Thyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 - openPR.com
Palantir Technologies (PLTR) Receives a Sell from RBC Capital - The Globe and Mail
As the Market Fluctuates in Response to President Donald Trump's Tariffs, What Stocks Are Safe? - The Globe and Mail
Graves Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Chardan Capital Weighs in on Tourmaline Bio FY2025 Earnings - Defense World
Best Stock to Buy Right Now: Costco vs. Realty Income - The Globe and Mail
Nasdaq (NDAQ) Gets a Buy from Barclays - The Globe and Mail
AGNC Investment Expects to Capitalize on Wide Spreads. But Is the High-Yield Dividend Stock a Buy? - The Globe and Mail
Chardan Capital Begins Coverage on Tourmaline Bio (NASDAQ:TRML) - Defense World
Ready to Jump After Recent Trade: Tourmaline Bio Inc (TRML) - Sete News
An analyst sees good growth prospects for New Fortress Energy Inc (NFE) - Sete News
TRML Stock Sees Surge of Approximately 19.36% in Last Five Days - knoxdaily.com
Chardan sets $70 target on Tourmaline Bio, cites lead asset By Investing.com - Investing.com Canada
Biogen (BIIB) to Release Quarterly Earnings on Thursday - Defense World
Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock By Investing.com - Investing.com Canada
Chardan Capital Initiates Coverage of Tourmaline Bio (TRML) with Buy Recommendation - MSN
Investing in Tourmaline Bio Inc (TRML) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
BARK Inc (BARK) did well last session? - uspostnews.com
STRL (Sterling Infrastructure Inc) has impressive results - uspostnews.com
Chardan Initiates Tourmaline Bio at Buy With $70 Price Target - marketscreener.com
Alliancebernstein L.P. Has $263,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tourmaline Bio Inc Stock (TRML) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):